Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sickle cell symptoms cause patients to miss work

Vendetti N et al. Presentation at Foundation for Sickle Cell Disease Research Annual Meeting, June 2018.

Key clinical point: Sickle cell patients reported missing work or being affected by their symptoms while working.

Major finding: Three-quarters of patients reported missing work in the last year because of SCD symptoms. This group reported missing a mean 37 days yearly.

Study details: Single-site survey-based study of 186 adults with SCD.

Disclosures: Pfizer sponsored the study. Mr. Vendetti is employed by Pfizer and holds Pfizer stock. A study coauthor is a Pfizer consultant.

Read the article.

Citation:

Vendetti N et al. Presentation at Foundation for Sickle Cell Disease Research Annual Meeting, June 2018.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Anemia

Gene therapy reverses sickle cell phenotype in small study, Esrick EB et al. ASH 2018, Abstract 1023

Sickle cell pain: Opioids appear safe for inpatients, Akinboro OA et al. ASH 2018, Abstract 315

Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3

Systematic review examines sickle cell trait complications, Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308